Lupin Limited (LUPIN)
Healthcare · Pharmaceuticals & Biotechnology · NSE
· Updated 14 July 2026
₹2,492.6
↑ 29.41% (1Y)
🎯 Key Takeaways
- Revenue grew 1.7% QoQ to ₹5,768 in Q3FY25.
Market Cap
₹1.04 L Cr
P/E Ratio
36.2
Div Yield
0.00%
Promoter
0.0%
📊 Quarterly Results (₹ Cr)
| Metric | Q4FY23 | Q1FY24 | Q2FY24 | Q3FY24 | Q4FY24 | Q1FY25 | Q2FY25 | Q3FY25 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 4,430 | 4,814 | 5,039 | 5,197 | 4,961 | 5,600 | 5,673 | 5,768 |
| Operating Profit | 615 | 879 | 958 | 1,067 | 1,026 | 1,309 | 1,383 | 1,410 |
| OPM % | 13.0% | 17.8% | 18.2% | 20.0% | 20.1% | 22.2% | 23.6% | 23.5% |
| Net Profit | 242 | 453 | 495 | 619 | 368 | 806 | 859 | 859 |
| EPS | ₹5.19 | ₹9.94 | ₹10.76 | ₹13.47 | ₹7.89 | ₹17.58 | ₹18.70 | ₹18.75 |
⚖️ Peer Comparison — Pharmaceuticals & Biotechnology
| Company | MCap (₹ Cr) | P/E | ROCE | ROE | D/E |
|---|---|---|---|---|---|
| Sun Pharmaceutical Industries Limited | 4.51 L Cr | 41.3 | 20.3% | 15.1% | 0.03 |
| Divi's Laboratories Limited | 1.79 L Cr | 72.4 | 22.1% | 16.6% | 0.00 |
| Torrent Pharmaceuticals Limited | 1.49 L Cr | 80.1 | — | — | — |
| Cipla Limited | 1.16 L Cr | 25.4 | 19.4% | 14.6% | 0.00 |
| Dr. Reddy's Laboratories Limited | 1.12 L Cr | 20.0 | 19.7% | 16.6% | 0.12 |
| Lupin Limited | 1.04 L Cr | 36.2 | — | — | — |
| Mankind Pharma Limited | 1.03 L Cr | 49.2 | — | — | — |
| Zydus Lifesciences Limited | 1.02 L Cr | 22.5 | — | — | — |
| Aurobindo Pharma Limited | 87,806 | 25.3 | — | — | — |
| Laurus Labs Limited | 71,455 | 356.8 | — | — | — |
🔗 Peer Stock Analyses
📋 Recent Filings
-
🟡 sustainability report 13 July 2026Lupin Limited's Business Responsibility and Sustainability Report for FY 2025-26 details its ESG performance, including a 41% reduction in Scope 1 and...
-
🔴 Corporate Action 8 July 2026Lupin announced its 44th AGM on August 4, 2026, and set July 17, 2026 as the record date for a proposed final dividend of ₹18 per share on the March 3...
-
🔴 Corporate Action 8 July 2026Lupin Limited announced on July 8, 2026 that its Operations and Finance Committee allotted 2,358 fully paid-up equity shares of ₹2 each by exercising ...
-
🟡 Board Meeting 8 July 2026Lupin Limited announced its 44th Annual General Meeting scheduled for August 4, 2026, where shareholders will vote on a proposed final dividend of ₹18...
-
Announcement 6 July 2026Lupin Limited announced its inclusion in TIME and Statista's World's Most Sustainable Companies 2026 list, ranking 318th out of 750 globally and among...
-
🟡 buyback redemption 1 July 2026Lupin announced completion of Nanomi's acquisition of 11,794,497 MPPI shares and MPPI's buyback of 61,118 shares on July 01, 2026, increasing Nanomi's...
-
Announcement 1 July 2026Lupin announced EMA approval for NaMuscla's expanded pediatric indication covering children aged 6-11 with non-dystrophic myotonic disorders, adding 6...
-
🟡 Board Meeting 30 June 2026Lupin Limited announced on June 30, 2026, that its Nomination and Remuneration Committee approved granting 65,251 stock options under the Lupin Employ...
-
Announcement 26 June 2026Lupin announced it received tentative U.S. FDA approval for its Abbreviated New Drug Application for Enzalutamide Tablets in 40 mg, 80 mg, 120 mg, and...
-
Financial Results 26 June 2026Lupin Limited announced that its trading window for securities will close on July 1, 2026, and remain closed until 48 hours after the unaudited financ...
Data sourced from stock announcements. Analysis generated by StockFin.ai.
For informational purposes only — not investment advice. Updated 2026-07-14.
📡 Get AI alerts when LUPIN files new disclosures
Track LUPIN filings, board meetings, and corporate actions. Free email alerts at 5 PM.
Track LUPIN — FreeFree account · 2 AI queries/day
© 2026 StockFin.ai — AI-powered Indian stock research